ZA202103820B - Capsule formulations - Google Patents
Capsule formulationsInfo
- Publication number
- ZA202103820B ZA202103820B ZA2021/03820A ZA202103820A ZA202103820B ZA 202103820 B ZA202103820 B ZA 202103820B ZA 2021/03820 A ZA2021/03820 A ZA 2021/03820A ZA 202103820 A ZA202103820 A ZA 202103820A ZA 202103820 B ZA202103820 B ZA 202103820B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- solid solution
- methods
- capsule formulations
- capsules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773848P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/063547 WO2020112961A1 (en) | 2018-11-30 | 2019-11-27 | Capsule formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202103820B true ZA202103820B (en) | 2026-03-25 |
Family
ID=70849818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/03820A ZA202103820B (en) | 2018-11-30 | 2021-06-03 | Capsule formulations |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US20200170957A1 (https=) |
| EP (3) | EP4487915A3 (https=) |
| JP (1) | JP7342124B2 (https=) |
| KR (1) | KR102586747B1 (https=) |
| CN (1) | CN113164403A (https=) |
| AR (1) | AR117219A1 (https=) |
| AU (1) | AU2019389031B2 (https=) |
| BR (1) | BR112021010285A2 (https=) |
| CA (1) | CA3120999C (https=) |
| CL (1) | CL2021001389A1 (https=) |
| CY (1) | CY1126079T1 (https=) |
| DK (2) | DK3886820T3 (https=) |
| ES (2) | ES2998858T3 (https=) |
| FI (2) | FI3886820T3 (https=) |
| HR (2) | HRP20230551T1 (https=) |
| HU (2) | HUE069633T2 (https=) |
| IL (1) | IL283450B2 (https=) |
| LT (2) | LT4233850T (https=) |
| MA (2) | MA54318B1 (https=) |
| MD (2) | MD3886820T2 (https=) |
| MX (1) | MX2021006242A (https=) |
| NZ (1) | NZ776554A (https=) |
| PL (2) | PL4233850T3 (https=) |
| PT (2) | PT4233850T (https=) |
| RS (2) | RS64250B1 (https=) |
| SG (1) | SG11202105572UA (https=) |
| SI (2) | SI4233850T1 (https=) |
| SM (2) | SMT202400521T1 (https=) |
| TW (1) | TWI827745B (https=) |
| WO (1) | WO2020112961A1 (https=) |
| ZA (1) | ZA202103820B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020112961A1 (en) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Capsule formulations |
| US11603356B2 (en) | 2019-11-08 | 2023-03-14 | Chemocentryx, Inc. | Amorphous form of a complement component C5a receptor |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| JP7839157B2 (ja) * | 2020-10-28 | 2026-04-01 | ケモセントリックス， インコーポレイテッド | 化膿性汗腺炎を処置する方法 |
| WO2022140258A1 (en) * | 2020-12-21 | 2022-06-30 | Chemocentryx, Inc. | Treatment of c3 glomerulopathy using a c5a inhibitor |
| CN119031903A (zh) * | 2022-05-19 | 2024-11-26 | 陶氏环球技术有限责任公司 | 基于peg的聚合物间复合物用于改善bcs ii类药物的增溶的用途 |
| WO2025203055A1 (en) * | 2024-03-26 | 2025-10-02 | Council Of Scientific And Industrial Research | Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| BRPI0518484A2 (pt) | 2004-11-24 | 2008-11-18 | Merck & Co Inc | composiÇço, cÁpsula, e, processo para preparar a mesma |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| CA2689137C (en) * | 2007-05-29 | 2017-05-02 | Intrexon Corporation | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| RS54998B1 (sr) | 2008-12-22 | 2016-11-30 | Chemocentryx Inc | Antagonisti c5ar |
| NZ602288A (en) * | 2010-03-10 | 2014-02-28 | Abbvie Bahamas Ltd | Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide |
| RS56332B1 (sr) * | 2010-06-24 | 2017-12-29 | Chemocentryx Inc | Antagonisti c5ar |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9074470B2 (en) | 2010-12-27 | 2015-07-07 | Seven Generations Energy Ltd. | Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources |
| WO2015118015A1 (en) | 2014-02-05 | 2015-08-13 | Lek Pharmaceuticals D.D. | Solid pharmaceutical compositions of androgen receptor antagonists |
| DK3200791T3 (da) | 2014-09-29 | 2020-05-25 | Chemocentryx Inc | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister |
| JP7339733B2 (ja) | 2016-01-14 | 2023-09-06 | ケモセントリックス，インコーポレイティド | Ｃ３腎症を処置する方法 |
| EP3439658B1 (en) | 2016-04-04 | 2021-11-24 | ChemoCentryx, Inc. | Soluble c5ar antagonists |
| TWI826364B (zh) | 2017-04-03 | 2023-12-21 | 德商因夫萊亞斯有限公司 | 活性抑制劑於發炎性疾病之治療 |
| CA3077395A1 (en) | 2017-10-30 | 2019-05-09 | Chemocentryx, Inc. | Deuterated compounds as immunomodulators |
| CA3078732A1 (en) | 2017-10-31 | 2019-05-09 | Chemocentryx, Inc. | C5ar inhibitor reduction of urinary scd163 |
| US11191756B2 (en) | 2018-06-07 | 2021-12-07 | Chemocentryx, Inc. | Dosing and effect of C5a antagonist with ANCA-associated vasculitis |
| WO2020112961A1 (en) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Capsule formulations |
-
2019
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/en not_active Ceased
- 2019-11-27 PT PT231602715T patent/PT4233850T/pt unknown
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 PL PL23160271.5T patent/PL4233850T3/pl unknown
- 2019-11-27 SI SI201930868T patent/SI4233850T1/sl unknown
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 EP EP24196793.4A patent/EP4487915A3/en active Pending
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 DK DK23160271.5T patent/DK4233850T3/da active
- 2019-11-27 EP EP23160271.5A patent/EP4233850B1/en active Active
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-27 MA MA62992A patent/MA62992B1/fr unknown
- 2019-11-27 ES ES23160271T patent/ES2998858T3/es active Active
- 2019-11-27 HU HUE23160271A patent/HUE069633T2/hu unknown
- 2019-11-27 SM SM20240521T patent/SMT202400521T1/it unknown
- 2019-11-27 MD MDE20231131T patent/MD4233850T2/ro unknown
- 2019-11-27 NZ NZ776554A patent/NZ776554A/en unknown
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/en active Active
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-27 LT LTEP23160271.5T patent/LT4233850T/lt unknown
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 FI FIEP23160271.5T patent/FI4233850T3/fi active
- 2019-11-27 RS RS20241401A patent/RS66362B1/sr unknown
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 IL IL283450A patent/IL283450B2/en unknown
- 2019-11-27 CA CA3120999A patent/CA3120999C/en active Active
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active Active
- 2019-11-27 HR HRP20241735TT patent/HRP20241735T1/hr unknown
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-27 SM SM20230153T patent/SMT202300153T1/it unknown
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
-
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-06-03 ZA ZA2021/03820A patent/ZA202103820B/en unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
-
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
-
2024
- 2024-02-09 US US18/437,368 patent/US20240299306A1/en not_active Abandoned
-
2025
- 2025-08-28 US US19/313,405 patent/US20250375385A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202103820B (en) | Capsule formulations | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| MX2017010544A (es) | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. | |
| MX2025010483A (es) | Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento | |
| PH12020550341A1 (en) | Niraparib formulations | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| JOP20220104A1 (ar) | نظام تجريع لعوامل مضادة لـ dll3 | |
| JOP20200041A1 (ar) | تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي | |
| PH12022551105A1 (en) | Tyk2 pseudokinase ligands | |
| SA519410320B1 (ar) | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل | |
| MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
| FR3034993B1 (fr) | Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques | |
| MX2024002360A (es) | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. | |
| NZ759295A (en) | 5-5 fused rings as c5a inhibitors | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| PH12021550055A1 (en) | Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized | |
| EA202191063A1 (ru) | Новая дозированная форма | |
| MX2019004200A (es) | Terapia de combinacion. | |
| EA202190247A1 (ru) | ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ | |
| TN2019000238A1 (en) | Methods for treating complement-mediated diseases and disorders | |
| EA202092278A1 (ru) | Римегепант для связанных с cgrp расстройств | |
| EA201992109A1 (ru) | Способы лечения опосредованных комплементом заболеваний и расстройств |